Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 1/20 | 0.42 |
| ▸ | HSPB1 | P04792 | 4/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30444837 | 1.00 | GLS (0.42) | GLSHSPB1S1PR4RAB9ANPC1 | |
| SCHEMBL29487166 | 0.89 | HSPB1 (0.44) | GLSHSPB1S1PR4SERPINE1MAPT | |
| SCHEMBL679255 | 0.89 | HSPB1 (0.44) | GLSHSPB1S1PR4SERPINE1MAPT | |
| SCHEMBL30445099 | 0.84 | HSPB1 (0.42) | GLSHSPB1S1PR4LMNAMAPK14 | |
| SCHEMBL23629534 | 0.84 | HSPB1 (0.42) | GLSHSPB1S1PR4LMNAMAPK14 | |
| SCHEMBL679462 | 0.76 | RXRA (0.39) | GLSHSPB1S1PR4RAB9ANPC1 | |
| SCHEMBL679110 | 0.76 | SERPINE1 (0.43) | GLSHSPB1S1PR4MAPK14SERPINE1 | |
| SCHEMBL5347812 | 0.75 | GLS (0.70) | GLSRAB9ANPC1LMNAMAPT | |
| SCHEMBL20770037 | 0.75 | GLS (0.55) | GLSRAB9ANPC1LMNAMAPT | |
| SCHEMBL680857 | 0.74 | MAPT (0.55) | HSPB1S1PR4RAB9ANPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11952364-B2 | TRK inhibitors useful as anticancer drugs | TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED (CN) | 2024-04-09 | — | — | US | disclosed |
| CN-112739691-B | TRK inhibitors as anticancer agents | 泰励生物科技（上海）有限公司 | 2023-05-23 | — | — | CN | disclosed |
| US-20220388983-A1 | TRK INHIBITORS USEFUL AS ANTICANCER DRUGS | TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED (CN) | 2022-12-08 | — | — | US | disclosed |
| EP-3848365-A1 | TRK INHIBITOR AS ANTI-CANCER DRUG | Tyligand Bioscience (Shanghai) Limited (CN) | 2021-07-14 | — | — | EP | disclosed |
| CN-112739691-A | TRK inhibitors as anticancer agents | 泰励生物科技（上海）有限公司 | 2021-04-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11952364-B2 | TRK inhibitors useful as anticancer drugs | NTRK1, NTRK3, MUSK | GLS 2436/4885HSPB1 940/4885S1PR4 3268/4885 |
| US-20220388983-A1 | TRK INHIBITORS USEFUL AS ANTICANCER DRUGS | NTRK1, NTRK3, MUSK | GLS 2436/4885HSPB1 940/4885S1PR4 3268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.